U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07178912) titled 'Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)' on Sept. 10.
Brief Summary: To find out if giving blinatumomab as injections under the skin and olverembatinib can help to control the disease in patients with Ph-positive ALL.
Study Start Date: Feb. 27, 2026
Study Type: INTERVENTIONAL
Condition:
Phase II Clinical Trial
Blinatumomab
Olverembatinib
Lymphoblastic Leukemia
Philadelphia Chromosome Positive
Intervention:
DRUG: Blinatumomab
Given by Iv
DRUG: olverembatinib
Given by P...